Nadim Ahmed (Bristol Myers Squibb)
Bristol Myers' top hematology exec is on his way out — right on the heels of a $6B CVR implosion
Fourteen days after the $6.3 billion CVR tied to the approval of liso-cel went up in smoke, one of the top execs in charge …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
